不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性自然杀伤/T 细胞淋巴瘤的耐药机制及潜在治疗策略
英文原题：Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer/T cell lymphoma.
查看英文原题
Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer/T cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
自然杀伤/T细胞淋巴瘤（NKTCL）是一种起源于NK或T细胞的恶性肿瘤，具有高度侵袭性和异质性。NKTCL主要与Epstein-Barr病毒感染相关，在亚洲和拉丁美洲人群中发病率较高。由于天冬酰胺酶和免疫治疗的应用，临床结局已显著改善。然而，对于一线治疗失败的患者，预后极差。多药耐药基因过表达、信号通路异常、表观遗传修饰以及活动性Epstein-Barr病毒感染可能是耐药的原因。本综述总结了NKTCL的耐药机制，并提出了潜在的治疗策略。
展开英文摘要原文
Natural killer/T cell lymphoma (NKTCL) is a malignant tumor originating from NK or T cells, characterized by its highly aggressive and heterogeneous nature. NKTCL is predominantly associated with Epstein-Barr virus infection, disproportionately affecting Asian and Latin American populations. Owing to the application of asparaginase and immunotherapy, clinical outcomes have improved significantly.
However, for patients in whom first-line treatment fails, the prognosis is exceedingly poor. Overexpression of multidrug resistance genes, abnormal signaling pathways, epigenetic modifications and active Epstein-Barr virus infection may be responsible for resistance. This review summarized the mechanisms of resistance for NKTCL and proposed potential therapeutic approaches.
论文信息
- 作者
- Wang C、Wang L
- 第一作者单位
- Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.China
- 文献类型
- 综述
- 期刊
- Chinese medical journal2024 Oct 5
- 原文标识
- PubMed 39175124 · DOI 10.1097/CM9.0000000000003152
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →